What are the main strategies employed by the Diabetes Prevention Program for women with gestational diabetes and pregnant or obese women during prenatal and postpartum periods?
What early risk factors for diabetes have been identified in pregnant women?
How effective is early prevention in reducing the risk of diabetes in women who plan to conceive?
What intelligent systems are being used to diagnose and predict foot complications in T2D?
What thermal imaging techniques are being used for AI analyses in diabetic foot prediction in T2D?
Can AI systems for diabetic foot prediction be expected to enter routine clinical use in the near future?
Diabetes is well known as a heterogeneous disease. What new approaches are being employed for its subclassification?
What associations have been found between cardiorenal syndrome and diabetes and what implications does any association between the two have for routine management?
Why is diabetes and cardiorenal syndrome considered as the ‘triple threat’?
What is your role as an advanced practice nurse working in primary care?
How important is medical education in addressing stigma?
How does stigma impact management of diabetes?
What are some of the unmet needs considering psychological issues in patients with diabetes?
Can better understanding of the psychosocial issues help overcome barriers in helping HCPs to more effectively treat their patients?
What is meant by adaptive intervention in epidemiological studies in diabetes and how is this different from past strategies?
What impact did FLEX (Flexible Lifestyle Empowering Change) intervention have on metabolic and psychosocial outcomes in young patients with type 1 diabetes?
What socio-economic and clinical aspects have been correlated with poor glycemic control considering different insulin regimes in younger patients and how can these findings contribute to better management?
What studies are being undertaken to better understand the mechanisms behind resistance to obesity?
How common is congenital leptin deficiency and how is it diagnosed and treated?
The discovery of leptin has changed our overall understanding of energy homeostasis. Can obesity also be related to defects in pathways downstream of leptin signaling?
What clinical implications have emerged from our greater understanding of the physiological mechanisms at the basis of obesity?
What’s new data on SGLT2 inhibitors and GLP-1 RAs was presented at ADA 2019?
What patient characteristics are used to guide the choice of an SGLT2 inhibitor or a GLP-1 RA?
Is it conceivable that nephrologists will be prescribing SGLT2 inhibitors and GLP-1 RAs in the future?